Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apyx Medical Co. stock logo
APYX
Apyx Medical
$1.45
-3.3%
$1.70
$1.21
$7.97
$50.23M1.09144,340 shs52,227 shs
Accuray Incorporated stock logo
ARAY
Accuray
$2.16
-1.8%
$2.51
$2.10
$4.30
$214.21M1.44445,765 shs117,965 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$9.96
-2.0%
$10.50
$3.89
$14.75
$232.77M1.11513,210 shs71,321 shs
Iradimed Corporation stock logo
IRMD
Iradimed
$41.39
-2.5%
$42.92
$36.12
$51.04
$524.00M0.8251,482 shs23,962 shs
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$6.69
-2.5%
$8.79
$3.78
$13.62
$369.42M1.67180,060 shs40,049 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apyx Medical Co. stock logo
APYX
Apyx Medical
+13.64%+13.64%+18.11%-34.50%-48.10%
Accuray Incorporated stock logo
ARAY
Accuray
-0.90%+0.46%-11.29%-21.15%-20.58%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-2.03%-8.22%-18.06%-87.53%-91.41%
Iradimed Corporation stock logo
IRMD
Iradimed
+1.29%+4.87%-1.19%-1.76%+5.60%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
0.00%-8.17%-19.67%-18.72%+17.26%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apyx Medical Co. stock logo
APYX
Apyx Medical
3.808 of 5 stars
3.54.00.04.20.01.70.6
Accuray Incorporated stock logo
ARAY
Accuray
3.615 of 5 stars
3.50.00.04.62.61.70.6
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.3187 of 5 stars
3.32.00.04.61.40.00.6
Iradimed Corporation stock logo
IRMD
Iradimed
4.8592 of 5 stars
3.54.01.74.42.83.31.3
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apyx Medical Co. stock logo
APYX
Apyx Medical
3.00
Buy$6.17325.29% Upside
Accuray Incorporated stock logo
ARAY
Accuray
3.00
Buy$8.25281.94% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.67
Moderate Buy$96.00863.86% Upside
Iradimed Corporation stock logo
IRMD
Iradimed
3.00
Buy$62.5051.00% Upside
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/A

Current Analyst Ratings

Latest APYX, PLSE, ARAY, INO, and IRMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Iradimed Corporation stock logo
IRMD
Iradimed
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
4/22/2024
Iradimed Corporation stock logo
IRMD
Iradimed
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$65.00
4/1/2024
Iradimed Corporation stock logo
IRMD
Iradimed
Singular Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
3/7/2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform
2/13/2024
Accuray Incorporated stock logo
ARAY
Accuray
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/13/2024
Accuray Incorporated stock logo
ARAY
Accuray
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
1/25/2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$48.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apyx Medical Co. stock logo
APYX
Apyx Medical
$52.35M0.96N/AN/A$0.78 per share1.86
Accuray Incorporated stock logo
ARAY
Accuray
$447.61M0.48N/AN/A$0.56 per share3.86
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$830K280.44N/AN/A$5.16 per share1.93
Iradimed Corporation stock logo
IRMD
Iradimed
$65.56M7.99$1.41 per share29.42$5.66 per share7.31
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$700K527.75N/AN/A$0.81 per share8.26

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$18.71M-$0.54N/AN/AN/A-35.75%-54.90%-28.41%5/9/2024 (Estimated)
Accuray Incorporated stock logo
ARAY
Accuray
-$9.28M-$0.15N/A15.43N/A-3.25%-28.11%-3.05%5/1/2024 (Confirmed)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$7.56N/AN/AN/A-16,238.91%-79.86%-57.71%5/8/2024 (Estimated)
Iradimed Corporation stock logo
IRMD
Iradimed
$17.19M$1.3630.43N/A26.22%24.62%20.43%5/2/2024 (Estimated)
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-$42.21M-$0.89N/AN/AN/A-112.74%-61.09%5/7/2024 (Confirmed)

Latest APYX, PLSE, ARAY, INO, and IRMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/AN/A
5/1/2024N/A
Accuray Incorporated stock logo
ARAY
Accuray
-$0.0050N/A+$0.0050N/AN/AN/A  
3/28/2024Q4 2023
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A-$0.21-$0.21-$0.20N/AN/A
3/21/2024Q4 2023
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$0.13-$0.19-$0.06-$0.10$14.40 million$14.66 million
2/8/2024Q4 2023
Iradimed Corporation stock logo
IRMD
Iradimed
$0.37$0.36-$0.01$0.36N/A$17.45 million
1/31/202412/31/2023
Accuray Incorporated stock logo
ARAY
Accuray
-$0.05-$0.10-$0.05-$0.10$107.11 million$107.24 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apyx Medical Co. stock logo
APYX
Apyx Medical
N/AN/AN/AN/AN/A
Accuray Incorporated stock logo
ARAY
Accuray
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Iradimed Corporation stock logo
IRMD
Iradimed
$0.601.45%N/A44.12%N/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apyx Medical Co. stock logo
APYX
Apyx Medical
1.23
5.52
4.74
Accuray Incorporated stock logo
ARAY
Accuray
3.53
1.58
0.84
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.60
3.60
Iradimed Corporation stock logo
IRMD
Iradimed
N/A
4.65
3.87
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A
6.76
6.76

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
55.33%
Accuray Incorporated stock logo
ARAY
Accuray
64.08%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Iradimed Corporation stock logo
IRMD
Iradimed
92.34%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
76.95%

Insider Ownership

CompanyInsider Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
13.10%
Accuray Incorporated stock logo
ARAY
Accuray
3.78%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50%
Iradimed Corporation stock logo
IRMD
Iradimed
42.60%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
69.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apyx Medical Co. stock logo
APYX
Apyx Medical
25234.64 million30.11 millionOptionable
Accuray Incorporated stock logo
ARAY
Accuray
1,02499.17 million95.42 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
12223.37 million22.79 millionOptionable
Iradimed Corporation stock logo
IRMD
Iradimed
14812.66 million7.27 millionOptionable
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
6155.22 million16.73 millionOptionable

APYX, PLSE, ARAY, INO, and IRMD Headlines

SourceHeadline
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
businesswire.com - April 24 at 4:05 PM
Pulse Biosciences to raise $60MPulse Biosciences to raise $60M
massdevice.com - March 29 at 10:48 AM
Q4 2023 Pulse Biosciences Inc Earnings CallQ4 2023 Pulse Biosciences Inc Earnings Call
finance.yahoo.com - March 29 at 10:48 AM
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023
investorplace.com - March 28 at 11:31 PM
Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023
finance.yahoo.com - March 28 at 7:45 PM
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial ResultsPulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
businesswire.com - March 28 at 4:12 PM
Pulse Biosciences Announces Plans to Initiate a Rights OfferingPulse Biosciences Announces Plans to Initiate a Rights Offering
businesswire.com - March 28 at 4:10 PM
PLSE Apr 2024 25.000 callPLSE Apr 2024 25.000 call
finance.yahoo.com - March 17 at 10:01 AM
PLSE Oct 2024 17.500 callPLSE Oct 2024 17.500 call
finance.yahoo.com - March 17 at 12:13 AM
PLSE Oct 2024 12.500 callPLSE Oct 2024 12.500 call
finance.yahoo.com - March 16 at 2:13 PM
PLSE Jul 2024 2.500 putPLSE Jul 2024 2.500 put
finance.yahoo.com - March 16 at 2:13 PM
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
businesswire.com - March 14 at 4:05 PM
Pulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearancePulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearance
msn.com - March 13 at 7:07 PM
FDA clears pulsed field ablation electrode tech from Pulse BiosciencesFDA clears pulsed field ablation electrode tech from Pulse Biosciences
massdevice.com - March 11 at 1:28 PM
What to know about low blood pressure with a high pulseWhat to know about low blood pressure with a high pulse
medicalnewstoday.com - March 10 at 2:46 PM
FDA clears Pulse Biosciences soft tissue ablation systemFDA clears Pulse Biosciences' soft tissue ablation system
investing.com - March 10 at 2:46 PM
Pulse Biosciences Gets FDA 510(k) Clearance For CellFX NsPFA Percutaneous Electrode SystemPulse Biosciences Gets FDA 510(k) Clearance For CellFX NsPFA Percutaneous Electrode System
markets.businessinsider.com - March 9 at 1:21 AM
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode SystemPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode System
stockhouse.com - March 8 at 3:19 PM
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode SystemPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
businesswire.com - March 8 at 1:17 PM
Pulse Biosciences reports positive 60-day evaluations for AFib-treating pulsed field ablationPulse Biosciences reports positive 60-day evaluations for AFib-treating pulsed field ablation
massdevice.com - February 14 at 12:51 PM
Pulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock UpPulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock Up
markets.businessinsider.com - February 14 at 12:51 PM
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility StudyPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
finance.yahoo.com - February 14 at 12:51 PM
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility StudyPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
businesswire.com - February 14 at 8:00 AM
Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In GrowthCompanies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth
finance.yahoo.com - February 2 at 12:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Apyx Medical logo

Apyx Medical

NASDAQ:APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Accuray logo

Accuray

NASDAQ:ARAY
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Inovio Pharmaceuticals logo

Inovio Pharmaceuticals

NASDAQ:INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Iradimed logo

Iradimed

NASDAQ:IRMD
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Pulse Biosciences logo

Pulse Biosciences

NASDAQ:PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.